NCT00964028View on ClinicalTrials.gov

Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

PHASE3CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

December 1, 2009

Primary Completion Date

April 12, 2010

Study Completion Date

April 12, 2010

Conditions

Haemophilus Influenzae Type bAcellular PertussisDiphtheriaTetanusPoliomyelitis

Interventions

BIOLOGICAL

Infanrix™-IPV/Hib

Intramuscular, three doses

Trial Locations (1)

543100

GSK Investigational Site, Wuzhou

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00964028 - Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) | Biotech Hunter | Biotech Hunter